Gain Therapeutics, Inc. (NASDAQ:GANX) Sees Significant Growth in Short Interest

Gain Therapeutics, Inc. (NASDAQ:GANX) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 149,600 shares, a growth of 8.3% from the March 31st total of 138,100 shares. Currently, 1.1% of the company’s shares are short sold. Based on an average daily trading volume, of 158,200 shares, the days-to-cover ratio is currently 0.9 days.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GANX shares. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Gain Therapeutics in a research report on Thursday, April 25th. Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a research report on Wednesday, March 27th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, April 23rd.

Gain Therapeutics Stock Up 1.4 %

Shares of NASDAQ GANX traded up $0.04 during midday trading on Wednesday, hitting $2.97. The stock had a trading volume of 57,798 shares, compared to its average volume of 150,410. The company has a market cap of $53.61 million, a P/E ratio of -1.74 and a beta of 0.43. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.04. The business’s 50 day moving average is $3.90 and its 200-day moving average is $3.44. Gain Therapeutics has a 52 week low of $2.00 and a 52 week high of $5.65.

Gain Therapeutics (NASDAQ:GANX) last issued its earnings results on Tuesday, March 26th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.03. As a group, analysts predict that Gain Therapeutics will post -1.22 EPS for the current year.

Insider Activity at Gain Therapeutics

In other news, Director Jeffrey Scott Riley bought 30,000 shares of Gain Therapeutics stock in a transaction on Thursday, March 28th. The shares were purchased at an average price of $3.86 per share, for a total transaction of $115,800.00. Following the acquisition, the director now owns 30,000 shares of the company’s stock, valued at $115,800. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 11.00% of the stock is owned by corporate insiders.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.